<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30876" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ursodeoxycholic Acid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Achufusi</surname>
            <given-names>Ted George O.</given-names>
          </name>
          <aff>SUNY University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Safadi</surname>
            <given-names>Anthony O.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahabadi</surname>
            <given-names>Navid</given-names>
          </name>
          <aff>A.T. Still University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ted George Achufusi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anthony Safadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Navid Mahabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30876.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ursodeoxycholic acid is a medication used to manage and treat cholestatic liver disease. This activity reviews the indications, mechanism of action, and contraindications for UDCA as a valuable agent in managing liver disease. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team performing patient management of cholestatic liver disease and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ursodeoxycholic acid.</p></list-item><list-item><p>Evaluate&#x000a0;the potential adverse effects of ursodeoxycholic acid.</p></list-item><list-item><p>Assess&#x000a0;appropriate monitoring needed for patients receiving therapy with ursodeoxycholic acid.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to advance the use of ursodeoxycholic acid and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30876&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30876">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30876.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ursodeoxycholic acid (UDCA), also known as ursodiol, has been used to treat liver disease for more than a hundred years. It was first employed in traditional Chinese medicine by herbalists and physicians alike. Before discovering its effectiveness in dissolving gallstones, its primary use was as a liver tonic.<xref ref-type="bibr" rid="article-30876.r1">[1]</xref><xref ref-type="bibr" rid="article-30876.r2">[2]</xref> Today, extensive evidence suggests that UDCA is beneficial in various types of liver pathology. However, most of the data still points to its therapeutic effect in treating gallstone disease.</p>
        <p>Gallstone disease is a common and exceedingly costly digestive disorder if considering the number of hospital admissions and cholecystectomies performed in the United States annually. It is a complex disorder where genetic and environmental factors contribute to the susceptibility to the disease. The primary non-invasive treatment for cholesterol gallstones is oral litholysis with bile acids. UDCA has been shown to decrease the biliary cholesterol saturation markedly and has found use as an alternative to cholecystectomy in patients with gallstone disease.<xref ref-type="bibr" rid="article-30876.r3">[3]</xref> Currently, gallstone disease is not an FDA-approved indication for UDCA use. Biliary sludge is considered to be another therapeutic target of UDCA therapy. It&#x02019;s an occurrence commonly precipitated by rapid weight loss, pregnancy, and total parenteral nutrition. A clinical study in which patients with idiopathic acute pancreatitis attributed to microscopic gallstones or biliary sludge showed complete resolution of gallbladder microlithiasis after UDCA treatment, demonstrating its therapeutic effect.<xref ref-type="bibr" rid="article-30876.r4">[4]</xref><xref ref-type="bibr" rid="article-30876.r1">[1]</xref></p>
        <p>UDCA is commonly used to treat patients with primary biliary cholangitis (formerly known as primary biliary cirrhosis), an immune-mediated cholestatic liver disease characterized by the destruction of intrahepatic bile ducts. UDCA is the only drug approved by the U.S. Food and Drug Administration to treat primary biliary cholangitis. Studies suggest that UDCA can significantly delay the progression of liver cirrhosis in patients with early stages of&#x000a0;primary biliary cholangitis (PBC).<xref ref-type="bibr" rid="article-30876.r5">[5]</xref><xref ref-type="bibr" rid="article-30876.r6">[6]</xref>&#x000a0;In&#x000a0;1 study, the probability of remaining free of extensive fibrosis or cirrhosis after UDCA treatment was 76% and 61% after being treated for 4 and 8 years, respectively.<xref ref-type="bibr" rid="article-30876.r7">[7]</xref> Similar results&#x000a0;have been observed in other case-control studies as well.</p>
        <p>UDCA&#x000a0;may&#x000a0;have a role in treating patients with primary sclerosing cholangitis. However, its use in PSC has not come without controversy. Primary biliary cirrhosis is a rare, progressive, immuno-mediated hepatobiliary disease. Currently, there is no proven medical therapy for patients with PSC, but UDCA has been established as therapy for those with the condition. The most significant&#x000a0;2 clinical trials of UDCA in PSC had somewhat disappointing results. One trial only showed a minimal trend toward statistically significant benefit with moderate doses of UDCA, and researchers terminated the other trial where high dose UDCA was used due to excessive adverse effects. Despite the lack of data regarding long-term efficacy, many experts still recommend moderate doses of UDCA in PSC. The lack of sufficient data regarding long-term efficacy might explain why PSC is not an FDA-approved indication for UDCA treatment.<xref ref-type="bibr" rid="article-30876.r8">[8]</xref>&#x000a0;</p>
        <p>Current data also supports UDCA treatment in intrahepatic cholestasis of pregnancy, a unique pregnancy-related disorder that can manifest during the late third trimester of pregnancy. In a recent meta-analysis that looked at 12 RCTs involving 662 patients with ICP, UDCA was associated with the resolution of pruritus, reduced serum levels of bile acids, and decreased serum levels of alanine aminotransferase. The same meta-analysis also demonstrated reduced adverse maternal and fetal outcomes among pregnant women with ICP.<xref ref-type="bibr" rid="article-30876.r9">[9]</xref> Despite the current data, the FDA does not list ICP as an indication for UDCA treatment. UDCA has also found use in the treatment of cystic fibrosis, graft vs host disease involving the liver, liver allograft rejection, bile duct-paucity syndromes such as biliary atresia, and non-alcoholic steatohepatitis. However, more studies are needed to determine the therapeutic potential of UDCA in these disorders, and the FDA has not approved the drug for treating these liver conditions.</p>
      </sec>
      <sec id="article-30876.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>UDCA&#x000a0;acts on the liver through various complex and complementary mechanisms, including alterations in the bile acid pool, serving as a cytoprotectant, immunomodulating substance, and choleretic. Furthermore, UDCA markedly decreases biliary cholesterol saturation by inhibiting the absorption of cholesterol in the intestine and its secretion into bile, demonstrated by reduced cholesterol fraction of biliary lipids.<xref ref-type="bibr" rid="article-30876.r1">[1]</xref><xref ref-type="bibr" rid="article-30876.r3">[3]</xref>&#x000a0;The cytoprotective effect of UDCA is attributable to its ability to protect hepatocytes and cholangiocytes from bile acid-induced damage. Bile acids stimulate the formation of reactive oxygen species, which induce inflammatory processes and cholecystitis.<xref ref-type="bibr" rid="article-30876.r10">[10]</xref> Evidence suggests that bile acids damage cells by causing mitochondrial dysfunction. UDCA offers cytoprotection in hepatic epithelia by preserving cell structures, including plasma membranes and mitochondria while stimulating anti-apoptotic pathways. Additionally, UDCA can prevent Kupffer cells, the resident macrophages in the liver, from generating reactive oxygen species, thus decreasing the level of oxidate stress in hepatocytes.<xref ref-type="bibr" rid="article-30876.r3">[3]</xref><xref ref-type="bibr" rid="article-30876.r11">[11]</xref></p>
        <p>Therapeutic concentrations of&#x000a0;UDCA can shift the concentration of bile acids from hydrophobicity to hydrophilicity.<xref ref-type="bibr" rid="article-30876.r12">[12]</xref> Hydrophobic bile acids, including deoxycholic acid and chenodeoxycholic acid, have been shown to have a toxic effect on hepatocytes by increasing cell membrane permeability and inducing apoptosis. There are suggestions that UDCA competitively displaces the endogenous bile acids at the level of ileal absorption or the hepatocyte level, thus decreasing the concentration of toxic hydrophobic bile acids while simultaneously increasing the absorption of hydrophilic bile acids.<xref ref-type="bibr" rid="article-30876.r4">[4]</xref> Depending on the dosage, UDCA and its conjugates account for approximately 19 to 64% of total biliary bile acids.<xref ref-type="bibr" rid="article-30876.r3">[3]</xref></p>
        <p>The choleretic effect of UDCA is attributable to its ability to induce the secretion of bile acids. This effect is comparable to endogenous bile acids; however, without the potential toxicity, which makes&#x000a0;it useful in treating cholestatic disorders. In fact, prior studies have shown that in patients with primary biliary cirrhosis and primary sclerosing cholangitis, UDCA therapy improved the excretion rates and transit time of bile acid analogs.<xref ref-type="bibr" rid="article-30876.r4">[4]</xref><xref ref-type="bibr" rid="article-30876.r13">[13]</xref> UDCA induces vesicular exocytosis in cholestatic hepatocytes by indirectly increasing intracellular calcium levels. In animal models, high levels of intracellular calcium were shown to stimulate transport proteins and vesicular exocytosis.<xref ref-type="bibr" rid="article-30876.r4">[4]</xref><xref ref-type="bibr" rid="article-30876.r14">[14]</xref> Other proposed mechanisms behind UDCA-induced choleresis include modulation of membrane transport proteins such as the chloride-bicarb anion exchanger (AE2), which&#x000a0;research&#x000a0;found to be diminished in the biliary epithelia of PBC patients. UDCA administration was found to upregulate the expression of the AE2 transporter when compared to the placebo group.<xref ref-type="bibr" rid="article-30876.r4">[4]</xref><xref ref-type="bibr" rid="article-30876.r15">[15]</xref></p>
        <p>UDCA has also been shown to have an immunomodulating effect on hepatocytes. In rats with extrahepatic obstruction caused by bile duct ligation,&#x000a0; researchers observed an increased hepatic expression of major histocompatibility complex class I antigens. Similarly, patients with cholestasis resulting&#x000a0;from primary biliary cirrhosis have the same aberrant expression of&#x000a0;major histocompatibility complex class I antigens on hepatocytes and bile duct&#x000a0;cells. Expression of these antigens could lead to immune-mediated destruction by activated&#x000a0;lymphocytes, causing hepatic injury. UDCA has been shown to reduce the expression of class I antigens in several cholestatic liver disorders.<xref ref-type="bibr" rid="article-30876.r16">[16]</xref></p>
      </sec>
      <sec id="article-30876.s4" sec-type="Administration">
        <title>Administration</title>
        <p>UDCA is a film-coated tablet available for oral administration. The absorption of the drug is enhanced by other bile acids; therefore, it is recommended to take the drug during meals with food to facilitate biliary secretion by the gallbladder.<xref ref-type="bibr" rid="article-30876.r17">[17]</xref>&#x000a0;The dosing of UDCA is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>For gallstone dissolution: 8 to 10 mg/kg/day orally divided into&#x000a0;3 or&#x000a0;4 doses.</p>
          </list-item>
          <list-item>
            <p>For gallstone prophylaxis: 300 mg orally twice daily.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30876.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>UDCA is a mostly well-tolerated drug. In most clinical trials, diarrhea was the most frequent adverse event observed during UDCA treatment in patients with gallstone disease, with a reported incidence of 2 to 9%. The mechanism behind this side effect is unclear. However, researchers have proposed that bacterial conversion of UDCA to&#x000a0;chenodeoxycholic acid, which serves as a potent secretory substance, could significantly contribute to this side effect. In patients with primary biliary cirrhosis, right upper quadrant abdominal pain was the most commonly reported side effect. Reports also exist of skin reactions in those with primary biliary cirrhosis. The most common dermatological manifestation was an exacerbation of pruritus, even though UDCA has demonstrated effectiveness in relieving pruritus in patients with PBC in other trials.<xref ref-type="bibr" rid="article-30876.r18">[18]</xref></p>
      </sec>
      <sec id="article-30876.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The use of&#x000a0;UDCA is contraindicated in patients with obstructive cholestasis due to a potential risk of biliary integrity disruption. Also, UDCA has not received approval for use in early pregnancy because of insufficient data regarding the risk of UDCA on the fetus during the first trimester of pregnancy.<xref ref-type="bibr" rid="article-30876.r19">[19]</xref></p>
      </sec>
      <sec id="article-30876.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There is limited data on the therapeutic index of UDCA. However, most data suggest that UDCA in doses of 5 to 25 mg/kg appears safe and well-tolerated. In patients with PBC, a dose of 13 to 15 mg/kg is preferred. The dose of 10 to 15 mg/kg used in most large trials was mostly for gallstone dissolution.<xref ref-type="bibr" rid="article-30876.r20">[20]</xref></p>
      </sec>
      <sec id="article-30876.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>UDCA has been shown to have potentially toxic molecular properties. UDCA breaks down into toxic lithocholic acid. After being absorbed in the small intestine, UDCA undergoes hepatic conjugation. Beyond conjugation, UDCA does not experience further breakdown by the liver or intestinal mucosa. It becomes oxidized or reduced, yielding either 7-keto-lithocholic acid or lithocholic acid. Litcholic acid can be toxic to liver cells and even cause liver failure in those with compromised sulfation. It also leads to segmental bile duct injury, hepatocyte failure, and death.<xref ref-type="bibr" rid="article-30876.r21">[21]</xref></p>
      </sec>
      <sec id="article-30876.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The large number of studies and data published on UDCA demonstrates the therapeutic effect of this drug on various forms of cholestatic liver disease. The efficacy of UDCA in primary biliary cholangitis is evident. Prolonged administration of&#x000a0;UDCA for patients with PBC is associated with a survival benefit and delaying of liver transplantation. There is evidence that it might even prevent the progression of the histologic stage of PBC. A comprehensive review of&#x000a0;3 randomized trials from the United States, Canada, and France included more than 500 patients with PBC treated with UDCA, with a median length of follow-up of 4 years.&#x000a0;Patients treated with UDCA had significantly longer transplant-free survival, with a 32% reduced risk of death or transplantation. However, it is essential to note that up to 40% percent of patients with PBC exhibit an inadequate response to UDCA and may continue to experience disease progression. In these cases, second-line agents merit consideration.<xref ref-type="bibr" rid="article-30876.r22">[22]</xref></p>
        <p>Recent data also suggest UDCA might have a role in managing PSC, cystic fibrosis, graft-versus-host-disease, and other hepatobiliary disorders; however, concrete data regarding therapeutic potential and long-term effects are currently lacking.&#x000a0;Due to its multi-functionality, it is difficult to envision a viable substitute agent for UDCA that combines as many hepatoprotective effects with similar efficacy. The significant progress made in understanding the anti-cholestatic mechanisms of UDCA has allowed for the successful testing of new therapeutic applications, even beyond liver and gallbladder disease. Several alternative drugs are under investigation in pre-clinical trials; however, unless an agent is proven more effective than the current therapy, UDCA most likely remains the go-to agent for treating cholestatic liver disease.</p>
        <p>The use of UDCA requires the involvement of the entire interprofessional healthcare team. Management of the drug includes monitoring by the pharmacist in tandem with the prescribing clinician (MD, DO, NP, PA). While the drug is safe, it can exacerbate pruritis and cause abdominal discomfort. The pharmacist should notify the clinician if the side effects become intolerable. Nursing can assess for therapeutic effectiveness and adverse events at follow-up visits, which is particularly important if the drug is used off-label, and report these to the rest of the team. As more data regarding indications and use of UDCA becomes available from ongoing research, all interprofessional healthcare team members need to keep current to drive patient outcomes optimally to effectively use UDCA, where it can provide therapeutic benefit.</p>
      </sec>
      <sec id="article-30876.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30876&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30876">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30876/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30876">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30876.s11">
        <title>References</title>
        <ref id="article-30876.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guarino</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Cocca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Altomare</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emerenziani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cicala</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed.</article-title>
            <source>World J Gastroenterol</source>
            <year>2013</year>
            <month>Aug</month>
            <day>21</day>
            <volume>19</volume>
            <issue>31</issue>
            <fpage>5029</fpage>
            <page-range>5029-34</page-range>
            <pub-id pub-id-type="pmid">23964136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makino</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>659</fpage>
            <page-range>659-64</page-range>
            <pub-id pub-id-type="pmid">9715413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roma</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Toledo</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Boaglio</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Basiglio</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Crocenzi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez Pozzi</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.</article-title>
            <source>Clin Sci (Lond)</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>121</volume>
            <issue>12</issue>
            <fpage>523</fpage>
            <page-range>523-44</page-range>
            <pub-id pub-id-type="pmid">21854363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazaridis</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Gores</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.</article-title>
            <source>J Hepatol</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>134</fpage>
            <page-range>134-46</page-range>
            <pub-id pub-id-type="pmid">11495032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Copaci</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Micu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Iliescu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Voiculescu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New therapeutical indications of ursodeoxycholic acid.</article-title>
            <source>Rom J Gastroenterol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-66</page-range>
            <pub-id pub-id-type="pmid">16200237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chascsa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Old and new treatments for primary biliary cholangitis.</article-title>
            <source>Liver Int</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>490</fpage>
            <page-range>490-499</page-range>
            <pub-id pub-id-type="pmid">28371104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seetharam</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.</article-title>
            <source>J Clin Exp Hepatol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>311</fpage>
            <page-range>311-318</page-range>
            <pub-id pub-id-type="pmid">28003721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabibian</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2018</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>293</fpage>
            <page-range>293-304</page-range>
            <pub-id pub-id-type="pmid">29991937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study).</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>40</issue>
            <fpage>e4949</fpage>
            <pub-id pub-id-type="pmid">27749550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>JBJ</given-names>
              </name>
              <name>
                <surname>Lajczak</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>O'Dwyer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Giddam</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>N&#x000ed; Gabhann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tambuwala</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Jefferies</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Keely</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Keely</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon.</article-title>
            <source>Am J Physiol Gastrointest Liver Physiol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>312</volume>
            <issue>6</issue>
            <fpage>G550</fpage>
            <page-range>G550-G558</page-range>
            <pub-id pub-id-type="pmid">28360029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ljubuncic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fuhrman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oiknine</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aviram</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bomzon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages.</article-title>
            <source>Gut</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-8</page-range>
            <pub-id pub-id-type="pmid">8949657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Combes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carithers</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Maddrey</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Luketic</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Shiffman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zetterman</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Risser</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hofmann</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.</article-title>
            <source>Hepatology</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>1649</fpage>
            <page-range>1649-54</page-range>
            <pub-id pub-id-type="pmid">10347103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jazrawi</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>de Caestecker</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Goggin</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Britten</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Northfield</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.</article-title>
            <source>Gastroenterology</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>106</volume>
            <issue>1</issue>
            <fpage>134</fpage>
            <page-range>134-42</page-range>
            <pub-id pub-id-type="pmid">8276175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heuman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Hepatoprotective properties of ursodeoxycholic acid.</article-title>
            <source>Gastroenterology</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>104</volume>
            <issue>6</issue>
            <fpage>1865</fpage>
            <page-range>1865-70</page-range>
            <pub-id pub-id-type="pmid">8500748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medina</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Ans&#x000f3;</surname>
              </name>
              <name>
                <surname>Vazquez</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis.</article-title>
            <source>Hepatology</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-7</page-range>
            <pub-id pub-id-type="pmid">8985258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hillaire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calmus</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gane</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ballet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moukthar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poupon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes.</article-title>
            <source>Gastroenterology</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>781</fpage>
            <page-range>781-8</page-range>
            <pub-id pub-id-type="pmid">8076765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saksena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Ursodeoxycholic acid in the treatment of liver diseases.</article-title>
            <source>Postgrad Med J</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>856</issue>
            <fpage>75</fpage>
            <page-range>75-80</page-range>
            <pub-id pub-id-type="pmid">9122101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hempfling</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dilger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Systematic review: ursodeoxycholic acid--adverse effects and drug interactions.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2003</year>
            <month>Nov</month>
            <day>15</day>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>963</fpage>
            <page-range>963-72</page-range>
            <pub-id pub-id-type="pmid">14616161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bessone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roma</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Is ursodeoxycholic acid detrimental in obstructive cholestasis? A propos of a case of malignant biliary obstruction.</article-title>
            <source>Ann Hepatol</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>442</fpage>
            <page-range>442-7</page-range>
            <pub-id pub-id-type="pmid">27049500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jazrawi</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orchard</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Theodossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Northfield</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>1069</fpage>
            <page-range>1069-76</page-range>
            <pub-id pub-id-type="pmid">10524634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotb</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of ursodeoxycholic acid toxicity &#x00026; side effects: ursodeoxycholic acid freezes regeneration &#x00026; induces hibernation mode.</article-title>
            <source>Int J Mol Sci</source>
            <year>2012</year>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>8882</fpage>
            <page-range>8882-8914</page-range>
            <pub-id pub-id-type="pmid">22942741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30876.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>154</fpage>
            <page-range>154-163</page-range>
            <pub-id pub-id-type="pmid">29928160</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
